Project Details
Description
VX15-440-101: A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-440 Combination Therapy in Subjects Aged 12 Years and Older With Cystic Fibrosis
| Status | Finished |
|---|---|
| Effective start/end date | 11/6/16 → 1/1/20 |
Funding
- Vertex Pharmaceuticals Incorporated
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.